面对如此积极的研究进展，慢乙肝患者及其家属都感到无比欣喜。对于这一群体而言，能够有新的治疗选择，无疑是更为重要的希望。随着后续临床数据的逐步公布，VRON-0200的应用前景将愈加明朗，有望为数以百万计的慢乙肝患者打开一扇新窗。

你是否也在为慢性乙型肝炎（慢乙肝）而烦恼？这种隐秘而又普遍的问题影响着全球近三亿人。近年来，医学界在慢乙肝的治疗上取得了一系列进展，其中Virion Therapeutics公司近期公布的VRON-0200免疫疗法的临床数据，给广大慢乙肝患者带来了新的希望！

However, its role in hepatitis B virus (HBV) replication has not been previously studied. In this study, we demonstrate that RNF5 effectively inhibits HBV replication by promoting the degradation of ...

Children and adults vaccinated on the recommended hep B series are afforded lifelong protection against the hepatitis B virus (HBV), a highly infectious virus that attacks the liver. Vaccination is ...

Help us make Medscape the best clinical resource possible. Please use this form to submit your questions or comments on how to make this resource center more useful to clinicians.